Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Neuropathix, Inc.

Neuropathix, Inc. Highlights Revenue Related to its Grant Award with NIH-NINDS
From Neuropathix, Inc.
Via AccessWire
Exposures COVID-19
Tickers NPTX
Neuropathix, Inc. Highlights Positive Preclinical Study Results on Lead Drug Candidate KLS-13019
From Neuropathix, Inc.
Via AccessWire
Tickers NPTX
Neuropathix, Inc. CEO Issues New Letter to Shareholders; Updates Market on Milestones in Research and Funding
From Neuropathix, Inc.
Via AccessWire
Tickers NPTX
Neuropathix, Inc. Welcomes Daniele Piomelli, PhD, MD to the Company’s Scientific Advisory Board
From Neuropathix, Inc.
Via AccessWire
Topics Cannabis Derivatives Intellectual Property
Exposures Cannabis Derivatives Intellectual Property
Tickers NPTX
Neuropathix, Inc. Receives Patent Grant from India for Its Novel Anti-Inflammatory Compounds
From Neuropathix, Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Tickers NPTX
Neuropathix, Inc. Chooses Purisys for Process Optimization and Scale Up of Its Lead Drug Candidate KLS-13019
From Neuropathix, Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Tickers NPTX
Neuropathix, Inc. Wholly Owned Subsidiary Kannalife Sciences, Inc. Awarded $2.97 Million Phase 2 Study Grant from National Institute of Neurological Disorders and Stroke (NINDS)
From Neuropathix, Inc.
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property Product Safety
Tickers NPTX
Neuropathix, Inc. Forms Dermique Incorporated its New Wholly Owned Subsidiary for the Ownership and Commercialization of the Company's Over-The-Counter Cosmeceutical Assets
From Neuropathix, Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Tickers NPTX
Neuropathix, Inc. Appoints Michael Ropacki, PhD to the Company's Scientific Advisory Board
From Neuropathix, Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Tickers NPTX
Neuropathix, Inc. Announces Publication of PCT Patent Application for the Treatment of Radiation Dermatitis and Other Skin Disorders
From Neuropathix, Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Tickers NPTX
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.